£40.6M
The Boston investor backs the clinical stage biotechnology firm to advance its immune-resetting therapies.
IR
Immune Regulation
Developing first-in-class immune-resetting therapies for autoimmune and allergic conditions.
United Kingdom
£40.6MTotal raised
Immune Regulation is a clinical stage biotechnology company developing therapies to reset the immune system for inflammatory and immunological diseases. The firm operates across the United States and the United Kingdom.
Categories
Team
JR
Jonathan Rigby
Group CEO